PMID- 1691459
OWN - NLM
STAT- MEDLINE
DCOM- 19900524
LR  - 20190726
IS  - 0028-3908 (Print)
IS  - 0028-3908 (Linking)
VI  - 29
IP  - 3
DP  - 1990 Mar
TI  - Enantiomeric differences in the effects of 3,4-methylenedioxymethamphetamine on 
      extracellular monoamines and metabolites in the striatum of freely-moving rats: 
      an in vivo microdialysis study.
PG  - 269-75
AB  - The effects of (+) and (-) 3,4-methylenedioxymethamphetamine (MDMA) and racemic 
      p-chloroamphetamine (PCA) on extracellular dopamine and its metabolites, 
      3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA), as well as 
      the metabolite of 5-hydroxytryptamine (5-HT), 5-hydroxyindoleacetic acid 
      (5-HIAA), were determined in dialysates of the striatum conscious rats by using 
      intracerebral dialysis and high performance liquid chromatography with 
      electrochemical detection (HPLC-EC). The (+) and (-)MDMA isomers (5, 10 mg/kg, 
      s.c.) and PCA (2.5, 5 mg/kg, s.c.) caused a rapid increase of extracellular 
      levels of dopamine and decreased extracellular levels of DOPAC and HVA 
      immediately after administration in dialysates of striatum. The order of potency 
      for this effect was PCA greater than (+)MDMA greater than (-)MDMA. The levels of 
      5-HIAA also decreased after the administration of drugs, but the effect had a 
      slower time course than DOPAC and HVA and did not exhibit an enantiomeric 
      difference. The data indicate that, although these drugs are thought to affect 
      the 5-HT neuronal system preferentially, they also affect dopamine systems and by 
      a mechanism in which the (+) isomer was more potent than the (-).
FAU - Hiramatsu, M
AU  - Hiramatsu M
AD  - Department of Pharmacology, UCLA School of Medicine 90024-1735.
FAU - Cho, A K
AU  - Cho AK
LA  - eng
GR  - DA 04206/DA/NIDA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - England
TA  - Neuropharmacology
JT  - Neuropharmacology
JID - 0236217
RN  - 0 (Amphetamines)
RN  - 0 (Biogenic Monoamines)
RN  - 102-32-9 (3,4-Dihydroxyphenylacetic Acid)
RN  - 333DO1RDJY (Serotonin)
RN  - 4764-17-4 (3,4-Methylenedioxyamphetamine)
RN  - 54-16-0 (Hydroxyindoleacetic Acid)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
RN  - R5J7E3L9SP (Fenclonine)
RN  - VTD58H1Z2X (Dopamine)
RN  - X77S6GMS36 (Homovanillic Acid)
SB  - IM
MH  - 3,4-Dihydroxyphenylacetic Acid/metabolism
MH  - 3,4-Methylenedioxyamphetamine/analogs & derivatives/*pharmacology
MH  - Amphetamines/*pharmacology
MH  - Animals
MH  - Biogenic Monoamines/*metabolism
MH  - Chromatography, High Pressure Liquid
MH  - Corpus Striatum/drug effects/*metabolism
MH  - Dialysis
MH  - Dopamine/metabolism
MH  - Electrochemistry
MH  - Fenclonine/pharmacology
MH  - Homovanillic Acid/metabolism
MH  - Hydroxyindoleacetic Acid/metabolism
MH  - Male
MH  - N-Methyl-3,4-methylenedioxyamphetamine
MH  - Rats
MH  - Rats, Inbred Strains
MH  - Serotonin/metabolism
MH  - Stereoisomerism
EDAT- 1990/03/01 00:00
MHDA- 1990/03/01 00:01
CRDT- 1990/03/01 00:00
PHST- 1990/03/01 00:00 [pubmed]
PHST- 1990/03/01 00:01 [medline]
PHST- 1990/03/01 00:00 [entrez]
AID - 10.1016/0028-3908(90)90012-g [doi]
PST - ppublish
SO  - Neuropharmacology. 1990 Mar;29(3):269-75. doi: 10.1016/0028-3908(90)90012-g.